Health
Novo Nordisk introduces "There's Only One Ozempic®" campaign, reuniting Justin Long and John Hodgman
Novo Nordisk today announced the launch of a new consumer campaign for Ozempic® (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, reinventing how traditional pharma advertising is being done. The campaign features the celebrated comedy pairing of actors Justin Long and John Hodgman, who first appeared together in a series of popular TV commercials in the mid-2000s. In this new campaign the duo combine levity, lively banter, and everyday moments to encourage informed and impactful dialogue between
About this update from Novo Nordisk A/s Class B
[{"type":"list","items":[{"val":[{"type":"text","content":"Campaign aims to meet adults living with type 2 diabetes where they are, using educational messages, levity, and lively banter to spotlight Ozempic®'s FDA-approved uses","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"Campaign focuses specifically on what makes the iconic Ozempic® (semaglutide) brand distinct in a crowded landscape of FDA-approved GLP-1s and unapproved compounded "semaglutide"","length":193,"tagName":"p"}]},{"val":[{"type":"text","content":"Goal is to encourage meaningful conversations between consumers and healthcare professionals through an unconventional approach to a pharma ad","length":142,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":507,"olType":false},{"type":"text","content":"PLAINSBORO, N.J., Jan. 20, 2026 /PRNewswire/ -- Novo Nordisk today announced the launch of a new consumer campaign for Ozempic® (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, reinventing how traditional pharma advertising is being done. The campaign features the celebrated comedy pairing of actors Justin Long and John Hodgman, who first appeared together in a series of popular TV commercials in the mid-2000s. In this new campaign the duo combine levity, lively banter, and everyday moments to encourage informed and impactful dialogue between people living with type 2 diabetes and their doctors about GLP-1 treatment options.","length":636,"tagName":"p"},{"type":"text","content":"Experience the full interactive Multichannel News Release here: https://www.multivu.com/novo-nordisk/9378751-en-novo-nordisk-theres-only-one-ozempic-campaign","length":157,"tagName":"p"},{"type":"text","content":"While Ozempic® is now a household name, by taking this unique, patient-focused approach, the campaign aims to educate on all the FDA-approved uses for Ozempic® and how this differentiates this iconic brand from other GLP-1s for the treatment of type 2 diabetes and unapproved compounded "semaglutide."","length":321,"tagName":"p"},{"type":"text","content":""Not all GLP-1s are the same, and people with type 2 diabetes should talk with their doctors about whether Ozempic® is right for them," said Ed Cinca, Senior Vice President, Marketing & Patient Solutions at Novo Nordisk Inc. "With our campaign, we're cutting through...